CAJ | 학술논문

肺动脉高压是指由各种原因引起的肺血管床结构和/或功能的改变，导致以肺血管阻力进行性升高为特点的临床综合症。最终致使右室扩张，引起心力衰竭，甚至死亡。近年来，靶向药物的出现使肺动脉高压患者预后得到明显改善。本文概括介绍肺动脉高压靶向药物的治疗进展。
폐동맥고압시지유각충원인인기적폐혈관상결구화/혹공능적개변，도치이폐혈관조력진행성승고위특점적림상종합증。최종치사우실확장，인기심력쇠갈，심지사망。근년래，파향약물적출현사폐동맥고압환자예후득도명현개선。본문개괄개소폐동맥고압파향약물적치료진전。
Pulmonary arterial hypertension (PAH) is deifned as a change of the structure and/or function of pulmonary vascular bed caused by a variety of reasons resulting in a clinical syndrome characterized by a progressive increase in pulmonary vascular resistance and finally leading to the expansion of right ventricular, heart failure, and even death. The prognosis of patients with pulmonary arterial hypertension has been signiifcantly improved along with the recent emerging of targeted drugs. The advances in the targeted therapy for pulmonary arterial hypertension are summarized in this review.